

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Dang, Duyen T.		POSITION TITLE Assistant Professor of Medicine	
eRA COMMONS USER NAME (credential, e.g., agency login) nndang			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Maryland, College Park, MD	BS & BS	1985-89	Zoology & Psychology
University of Pennsylvania, Philadelphia, PA		1989-91	Medicine
Harvard Medical School, Boston, MA	MD	1991-94	Medicine
University of Minnesota, Minneapolis, MN		1994-96	Internal Medicine
Presbyterian Medical Center, Philadelphia, PA		1996-97	Internal Medicine
Johns Hopkins University, Baltimore, MD		1997-2001	Gastroenterology

**A. Research and Professional Experience****Employment**

- 07/91-06/92 Harvard Medical School, Department of Genetics. *Sarnoff fellow*. Project: Generation of embryonic mosaics and determination of gene structure of *porcupine*, a segment polarity gene in *Drosophila*. Mentor: Dr. Norbert Perrimon.
- 07/94-06/96 The University of Minnesota Hospitals & Clinics. *Internal medicine resident*. Chairman: Dr. Tom Ferris and Dr. Jonathan Ravdin.
- 07/96-06/97 Presbyterian Medical Center of the University of Pennsylvania. *Internal medicine resident*. Chairman: Dr. Jack Warner and Dr. Edward Holmes.
- 07/97-06/01 The Johns Hopkins University School of Medicine, Department of Medicine, Division of Gastroenterology. *Gastroenterology fellow*. Chairman: Dr. Ed Benz.
- 07/98-06/01 The Johns Hopkins University School of Medicine, Department of Medicine, Division of Gastroenterology. *Postdoctoral fellow*. Project: The role of the gut-enriched Krüppel-like factor in intestinal tumorigenesis. Mentor: Dr. Vincent Yang.
- 08/03-present The University of Michigan Medical Center, Department of Internal Medicine, Division of Gastroenterology. *Assistant Professor*. Chairman: Dr. Marc Lippman and Dr. Robert Todd.
- 09/08-present VA Ann Arbor Healthcare System, Department of Medicine, Division of Gastroenterology. *Assistant Professor*. Chairman: Dr. Richard Mosely.

**Honors**

- 1986-89 General Honors Academic Scholarships, University of Maryland, College Park, MD
- 1989 Cum Laude and General Honors, University of Maryland, College Park, MD
- 1991 Sarnoff Endowment for Cardiovascular Research Fellowship
- 2000 Sarnoff Endowment for Cardiovascular Research Scholar Award
- 2001 Johns Hopkins Clinician Scientist Award
- 2006 Elizabeth C. Crosby Women in Science and Engineering Award, University of Michigan

**Professional Societies**

- 2000- American Gastroenterological Association
- 2003- AGA Abstract Reviewer
- 2004- Member, Michigan GI Peptide Research Center
- 2005- Member, UM Comprehensive Cancer Center

**Peer-reviewed publications.** \* Denotes corresponding author

1. **Dang DT**, Perrimon N\* (1992) Use of a yeast site-specific recombinase to generate embryonic mosaics in *Drosophila*. *Developmental Genetics* 13: 367-375.
2. Yin JC, Wallach JS, Wilder EL, Klingensmith J, **Dang D**, Perrimon N, Zhou H, Tully T, Quinn WG\* (1995) A *Drosophila* CREB/CREM homolog encodes multiple isoforms, including a cyclic AMP-dependent protein kinase-responsive transcriptional activator and antagonist. *Molecular and Cellular Biology* 15: 5123-5130.
3. Zhang W, Geiman DE, Shields JM, **Dang DT**, Mahatan C., Kaestner KH, Biggs JR, Kraft AS, Yang VW\* (2000) The gut-enriched Krüppel-like factor mediates the transactivating effect of p53 on the *p21<sup>WAF1/Cip1</sup>* promoter. *Journal of Biological Chemistry* 275: 18391-18398.
4. **Dang DT**, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, Yang VW\* (2000) Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. *FEBS Letters* 476: 203-207.
5. **Dang DT**, Pevsner J, Yang VW (2000) The biology of the mammalian Krüppel-like family of transcription factors. *International Journal of Biochemistry & Cell Biology* 32 (11-12): 1103-21.
6. Chen XM, Johns DC, Geiman DE, Marban E, **Dang DT**, Hamlin G, Sun R, Yang VW\* (2001) Gut-enriched Krüppel-like factor (Krüppel-like factor 4) inhibits cell proliferation by blocking G1/S progression of the cell cycle. *Journal of Biological Chemistry* 276: 30423-30428.
7. **Dang DT**, Mahatan CS, Dang LH, Agboola IA, Yang VW\* (2001) Expression of the gut-enriched Krüppel-like factor (Krüppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on *CDX2*. *Oncogene* 20 (35): 4884-4890.
8. **Dang DT**, Mahatan CS, Geiman DE, Yang VW\* (2002) Opposing effects of Krüppel-like factor 4 (gut-enriched Krüppel-like factor) and Krüppel-like factor 5 (intestinal-enriched Krüppel-like factor) on the promoter of the *Krüppel-like factor 4* gene. *Nucleic Acids Research*, 30 (13): 2736-2741.
9. Torbenson M\*, Marinopoulos S, **Dang DT**, Choti M, Ashfaq R, Maitra A, Boitnott J, Wilentz RE (2002) Smad4 overexpression in hepatocellular carcinoma is strongly associated with TGF-beta immunolabeling. *Human Pathology*, 33 (9): 871-876.
10. **Dang DT\***, Chen XM, Feng J, Torbenson M, Yang VW (2003) Over-expression of gut-enriched kruppel-like factor (GKLF or KLF4) in the human colon cancer cell line RKO leads to reduced tumorigenicity. *Oncogene*, 22 (22):3424-3430.
11. **Dang D\***, Cromwell DM (2003) Images in clinical medicine: Intussusception. *New England Journal of Medicine*, 350(3):e2.
12. **Dang DT\***, Chen F, Kohli M, Rago, C, Cummins JM, Dang LH\* (2005) Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. *Cancer Research* 65(20): 9485-9494.
13. Dang LH, Chen F, Ying C, Chun SY, Knock SA, Appelman HD, **Dang DT\***. (2006) CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48. *Oncogene*, 25(15):2264-72.
14. Dang LH, Chen F, Knock SA, Huang EH, Feng J, Appelman HD, **Dang DT\***. (2006) CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45. *Oncogene* 25(14):2048-59.
15. **Dang DT**, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH\*. (2006) HIF-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. *Cancer Research*, 66(3):1684-936.
16. Chun SY, Chen F, Washburn JG, MacDonald JW, Innes KL, Cruz-Correa MR, Dang LH, **Dang DT** (2007) CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3. *Oncogene*, 26(32):4725-9.
17. Ben-Shoshan M, Amir S, **Dang DT**, Dang LH, Weisman Y and Mabeesh NJ\* (2007) 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (Calcitriol) reduces VEGF via the HIF pathway in human cancer cells. *Molecular Cancer Therapeutics*, 6(4):1433-9.
18. **Dang DT**, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabeesh NJ, Heath E, Vogelzang NJ, Cruz-Correa M, Blayney DW, Ensminger WD, St. Croix B, Dang NH, Dang LH\* (2008) Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.. *Cancer Research*, 68(6): 1872-80. PMID: 18339868

19. Kwon Y, Elmunzer BJ, **Dang DT (2009)** Gastrointestinal stromal tumor complicated by Streptococcus Milleri bacteremia and liver abscess. *European Journal of Gastroenterology & Hepatology*, in press.
20. Burkitt K, Chun SY, **Dang DT**, Dang LH (**2009**) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.. *Molecular Cancer Therapeutics*, 2009 May 12. [Epub ahead of print]. PMID: 19435875

## GRANT SUPPORT

### ACTIVE

Sponsor: NIH/NCI R21CA115809

Title: The role of GSTP1 in oncogenic K-RAS signaling

Role: PI

% Effort: 4 calendar months

Dates and direct costs of entire project: 1/1/07-12/31/08, \$275,0000, with no cost extension until 12/31/09

Dates and direct costs of current year: 1/1/09-12/31/09, no cost extension.

Specific Aims of project: This project examines the role of GSTP1 in oncogenic K-RAS signaling in colorectal cancer cells. The specific aims are: 1) To determine the mechanisms by which GSTP1 mediates oncogenic K-RAS activation of MEK and ERK, (2) To determine the mechanisms by which GSTP1 reduces oxidative stress generated by oncogenic K-RAS, and (3) To determine the role of GSTP1 in oncogenic K-RAS-promoted tumorigenicity in vivo.

### PENDING

Sponsor: United States Department of Veterans Affairs 1101BX000406-01

Title: Mechanisms of CDX2 regulation of the IGF axis

Role: PI

% Effort: 4 calendar months

Dates and direct costs of entire project: 10/1/2009-9/30/2013, \$650,000.

Specific Aims of project: This proposal examines the role of CDX2 and p53 in IGF signaling. The specific aims are as follows: 1: To determine the mechanisms by which CDX2 and p53 regulate IGFBP3. 2: To determine the effects of CDX2 and p53 on the IGF axis. 3: To determine the effects of CDX2 and p53 on tumor growth and response to IGF axis inhibitors.

### COMPLETED

K08DK59970

8/1/01-7/31/06

NIH/NIDDK

Title: The role of transcription factors in APC signaling.

Role: PI

Research Scholar Award

07/01/01-06/30/04

AGA

Title: The role of transcription factors in APC signaling.

Role: PI

Pilot Feasibility Grant

9/01/04-08/31/05

Michigan GI Peptide Research Center

NIH P01 5P03DK034933-20 (PI: Owyang)

Title: Pilot study of the role of GSTP1 in tumorigenesis.

Role: PI